For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical ...

The integration of artificial intelligence (AI) into healthcare has opened new frontiers for improving patient care and ...

A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods g | ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

Research led by Brock University has found a possible cure for lung diseases typically found in older adults, such as pulmonary fibrosis. The findings are published in the journal Aging Cell.

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — ...

Time-travelling drama about the Japanese American legends of US military history.

The Indian rupee hit an all-time low on Friday, pressured by a firm dollar and as regional currencies stayed on the defensive ahead of the keenly awaited U.S. nonfarm payrolls report.